TME Pharma

Expanded Access (sometimes termed as compassionate use, early access or emergency use) refers to the use of an investigational drug outside of a clinical trial, with the primary purpose of treating a serious or immediately life-threatening disease or condition in a patient who has exhausted their treatment options and are not eligible for, or able to participate in a clinical trial. Expanded Access is different from clinical trials in that more comprehensive information about safety and effectiveness are required to be collected in clinical trials.

At this time, TME Pharma is not offering Expanded Access for NOX-A12.  Access to NOX-A12-based therapies is currently available only through participation in our clinical trials which allows us to allocate available supply to study the drug’s effectiveness and safety in a controlled and evaluable setting. For more information on our clinical trials that may be recruiting new patients, please consult We believe investigational products should be studied within the context of a clinical trial and encourage patients to enroll in a clinical trial wherever possible.

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.